Profile data is unavailable for this security.
About the company
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
- Revenue in USD (TTM)0.00
- Net income in USD-132.00m
- Incorporated2005
- Employees65.00
- LocationLarimar Therapeutics IncTHREE BALA PLAZA EAST. SUITE 506BALA CYNWYD 19004United StatesUSA
- Phone+1 (617) 622-4003
- Fax+1 (302) 655-5049
- Websitehttps://larimartx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OmniAB Inc | 21.09m | -63.67m | 243.28m | 114.00 | -- | 0.8769 | -- | 11.53 | -0.5906 | -0.5906 | 0.1956 | 1.93 | 0.0658 | -- | 6.40 | 185,035.10 | -19.86 | -- | -20.75 | -- | 27.71 | -- | -301.83 | -101.09 | 4.96 | -- | 0.00 | -- | -22.75 | 7.58 | -22.55 | -- | 49.04 | -- |
| Shattuck Labs Inc | 1.00m | -54.90m | 247.42m | 44.00 | -- | 2.65 | -- | 247.42 | -1.02 | -1.02 | 0.0178 | 1.48 | 0.0094 | -- | -- | 22,727.27 | -51.77 | -32.04 | -56.50 | -35.04 | -- | -- | -5,489.50 | -721.60 | -- | -- | 0.00 | -- | 245.26 | -10.36 | 13.62 | -- | -33.97 | -- |
| Crescent Biopharma Inc | 0.00 | -55.96m | 254.35m | 4.00 | -- | 1.14 | -- | -- | -21.97 | -21.97 | 0.00 | 8.40 | 0.00 | -- | -- | 0.00 | -72.70 | -55.66 | -86.54 | -62.83 | -- | -- | -- | -2,068.09 | -- | -- | 0.00 | -- | -100.00 | -- | -2.66 | -- | -41.45 | -- |
| Sutro Biopharma Inc | 105.65m | -216.77m | 256.67m | 178.00 | -- | -- | -- | 2.43 | -25.98 | -25.98 | 12.61 | -10.25 | 0.3194 | -- | 19.98 | 340,793.60 | -65.54 | -31.36 | -94.60 | -37.63 | -- | -- | -205.18 | -152.29 | -- | -- | -- | -- | -59.64 | 7.74 | -112.99 | -- | -2.30 | -- |
| Palisade Bio Inc | 0.00 | -11.23m | 259.27m | 8.00 | -- | 4.94 | -- | -- | -2.98 | -2.98 | 0.00 | 0.3522 | 0.00 | -- | -- | 0.00 | -137.67 | -130.84 | -221.20 | -165.85 | -- | -- | -- | -31,830.91 | -- | -1,041.55 | 0.0616 | -- | -100.00 | -- | -17.38 | -- | -- | -- |
| Avalo Therapeutics Inc | 192.00k | -99.70m | 261.13m | 23.00 | -- | 2.80 | -- | 1,360.05 | -8.79 | -8.79 | 0.0169 | 5.14 | 0.0017 | -- | -- | 8,347.83 | -89.35 | -94.60 | -128.95 | -128.31 | 54.69 | 81.11 | -52,019.79 | -790.66 | -- | -9.83 | 0.0248 | -- | -77.08 | -42.05 | -11.37 | -- | -- | -- |
| Neurogene Inc | 0.00 | -85.13m | 263.33m | 107.00 | -- | 0.9459 | -- | -- | -4.12 | -4.12 | 0.00 | 17.97 | 0.00 | -- | -- | 0.00 | -37.67 | -27.58 | -40.40 | -29.44 | -- | -- | -- | -28,431.03 | -- | -- | 0.0001 | -- | -- | -- | -106.91 | -- | -1.67 | -- |
| Larimar Therapeutics Inc | 0.00 | -132.00m | 266.72m | 65.00 | -- | 1.98 | -- | -- | -1.93 | -1.93 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -64.96 | -45.05 | -76.53 | -50.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -118.15 | -- | -7.58 | -- |
| Aardvark Therapeutics Inc | 0.00 | -48.77m | 267.38m | 33.00 | -- | 2.18 | -- | -- | -2.53 | -2.53 | 0.00 | 5.63 | 0.00 | -- | -- | -- | -44.96 | -- | -47.90 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -185.63 | -- | -- | -- |
| Nautilus Biotechnology Inc | 0.00 | -62.81m | 269.03m | 124.00 | -- | 1.59 | -- | -- | -0.4982 | -0.4982 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -27.27 | -20.34 | -28.36 | -20.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.16 | -- | 18.04 | -- |
| Minerva Neurosciences Inc | 0.00 | -14.03m | 272.20m | 8.00 | -- | -- | -- | -- | -1.85 | -1.85 | 0.00 | -4.94 | 0.00 | -- | -- | 0.00 | -39.57 | -35.73 | -44.01 | -37.64 | -- | -- | -- | -263.85 | -- | -- | 2.36 | -- | -- | -- | 104.80 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -158.52m | 274.36m | 148.00 | -- | 1.97 | -- | -- | -2.51 | -2.51 | 0.00 | 1.45 | 0.00 | -- | -- | 0.00 | -80.43 | -40.80 | -97.39 | -43.86 | -- | -- | -- | -- | -- | -- | 0.1371 | -- | -- | -- | -71.21 | -- | 26.12 | -- |
| OpGen Inc | 9.00m | 6.70m | 285.71m | 1.00 | 42.75 | 27.91 | 41.46 | 31.75 | 0.6585 | 0.6585 | 0.8894 | 1.01 | 0.994 | -- | 4.42 | 9,000,000.00 | 75.58 | -74.71 | 81.77 | -111.02 | 100.00 | 30.79 | 76.04 | -602.64 | -- | -- | 0.00 | -- | 52.01 | 8.23 | 134.76 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -56.17m | 286.00m | 17.00 | -- | 13.68 | -- | -- | -1.80 | -1.80 | 0.00 | 0.2852 | 0.00 | -- | -- | 0.00 | -159.13 | -77.37 | -195.99 | -84.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 19.04 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Larimar Therapeutics Inc's reporting currency: US Dollar USD
36.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2025 | 6.05m | 7.06% |
| Millennium Management LLCas of 30 Sep 2025 | 4.90m | 5.72% |
| Opaleye Management, Inc.as of 30 Sep 2025 | 3.72m | 4.35% |
| RTW Investments LPas of 30 Sep 2025 | 3.13m | 3.65% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.97m | 3.47% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.74m | 3.20% |
| AIGH Capital Management LLCas of 31 Dec 2025 | 2.00m | 2.34% |
| Adage Capital Management LPas of 30 Sep 2025 | 1.90m | 2.22% |
| Alyeska Investment Group LPas of 30 Sep 2025 | 1.89m | 2.21% |
| Woodline Partners LPas of 30 Sep 2025 | 1.62m | 1.90% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
